Ambry Genetics News and Activities

Ambry Genetics is owned by Tempus.

Tempus is a company listed under the stock ticker TMPS (US).

Tempus has 3 subsidiaries including Ambry Genetics, Deep 6 AI and Paige.

They are in:

• Biotechnology75%
• Software25%

Acquisition, funding and merger involving Tempus.

• Tempus has acquired Paige (posted on August 22 2025).

View the org chart displaying its 13 main executives

Most searched biographies at Ambry Genetics

• Tom Schoenherr, Chief Executive Officer
• Michelle Smith, General Counsel
• Samuel Giardina, Regional Vice President, West

Popular executive movements at Ambry Genetics

• Mickie Henshall, Chief Marketing Officer, has left the company  (posted on April 30 2026).

Popular executive movements at Tempus

• Kelli Teno-Manalli has joined the company as Vice President, Head of Communications  (posted on June 15 2026).

Create your alert
to follow the executive moves at Ambry Genetics.

Tempus has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Ambry Genetics

• Genetics in Medicine Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing 
• Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
• Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
• Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield 
• Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity  
• Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
• Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
• New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
• Ambry Genetics Data Supports Functional Study of BRCA2 Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers 
• Ambry Genetics Expands Its Award Collection with Three New Comparably Best Place to Work Honors for 2024
• View more press releases Close

Social media about Ambry Genetics

• Ambry Genetics on Wikipedia, Google News & Yahoo Finance
• Ambry Genetics on LinkedIn, X (Twitter) & YouTube